Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 19, 2024 (2 years ago)

phenylephrine in 0.9% Sodium Chloride Inj

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

phenylephrine in 0.9% Sodium Chloride Inj, 1mg per 10 mL (100 mcg/mL), Rx only, Hikma Injectables USA Inc., 36 Stults Road, Dayton, NJ 08810, NDC 63037-173-25

Affected NDC 63037-0173-25

Compare with the code on your package — it is the most precise check available.

Drug: Phenylephrine

Recalling firm
Hikma Injectables USA Inc
NDC code
63037-173-25
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0174-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenylephrine recalls

See all

Other recalls by Hikma Injectables USA Inc

All 2024 recalls
Class II · Moderate risk

ketamine inj 50 mg per 1 mL

Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.

Terminated Sterility / contamination Hikma Injectables USA Inc NDC 63037-137-25 D-0173-2025